

IBD REWIND

BEST OF 2023

JANUARY 31st, 2024 | h. 6:00 pm CET

Scientific directors: *Silvio Danese, Laurent Peyrin-Biroulet*

Inflammatory bowel disease (IBD) including Crohn's disease (CD) and Ulcerative Colitis (UC) are chronic diseases that significantly impact on patients' lives. Novel diagnostic and interventional techniques, imaging modalities and the introduction of biologics and small molecule have dramatically improved their management and outcomes. Our main focus on this webinar is to summarize the scientific literature of 2023 and assess their impact in IBD clinical practice.

FACULTY



Silvio Danese
Director, Gastroenterology and Endoscopy
IRCCS Ospedale San Raffaele, Milan, Italy
Professor of Gastroenterology
University Vita-Salute San Raffaele, Milan, Italy



Laurent Peyrin-Biroulet
Full Professor of Medicine IBD Unit
Department of Gastroenterology
Nancy University Hospital, France



Alessandro Armuzzi
Full Professor of Gastroenterology,
Lead IBD Center, Humanitas Research Hospital,
Humanitas University, Milan, Italy



Fernando Magro
Professor Pharmacology and Therapeutics
University of Porto - Porto, Portugal
Consultant gastroenterologist,
Centro Hospitalar de São João
and Director of Clinical Pharmacology
Founded the Portuguese IBD Group (GEDII)

Welcome and Intro of meeting objectives 5'

Silvio Danese, Italy - Laurent Peyrin-Biroulet, France

Monitoring in IBD 15'

Laurent Peyrin-Biroulet, France

Conventional and advanced therapy in IBD 15'

Alessandro Armuzzi, Italy

Safety of advanced therapies in IBD 15'

Fernando Magro, Portugal

What's new in IBD? 15'

Silvio Danese, Italy

Q&A session 10'

[CLICK HERE
TO REGISTER](#)

This educational activity is independent and it is sponsored by Abbvie, Janssen Pharmaceutica, Eli Lilly and Abivax

abbvie

janssen Immunology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

Lilly

ABIVAX

ibdscope.com



ORGANIZING SECRETARIAT
Materia Prima srl
segreteria@materia1a.it | www.materia1a.it
ibdscope@ibdscope.com